On Friday, Vir Biotechnology, Inc. ( VIR ) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B.

Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV).

The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths are associated with the disease.

Also Read: Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?

Participants in the trial received tobevibart and elebsiran alone (doublet regimen) or in combination with PEG-IFNα (triplet regimen).

The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (